Development of a framework for enhancing the transparency, reproducibility and communication of the benefit-risk balance of medicines

Clin Pharmacol Ther. 2011 Feb;89(2):312-5. doi: 10.1038/clpt.2010.291. Epub 2010 Dec 15.

Authors

P M Coplan¹, R A Noel, B S Levitan, J Ferguson, F Mussen

Affiliation

¹ Risk Management and Epidemiology, Purdue Pharma LP, Stamford, Connecticut, USA. [email protected]

PMID: 21160469
DOI: 10.1038/clpt.2010.291

No abstract available

MeSH terms

Communication
Decision Making
Drug Industry*
Drug-Related Side Effects and Adverse Reactions*
Product Surveillance, Postmarketing
Reproducibility of Results
Risk Assessment*
Statistics as Topic